search
Back to results

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Primary Purpose

Carcinoma, Non-Small-Cell Lung

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Savolitinib
Osimertinib
Pemetrexed
Cisplatin
Carboplatin
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carcinoma focused on measuring Savolitinib, Osimertinib, EGFR, Amplified, Metastatic, MET Driven, carcinoma, NSCLC, overexpressed

Eligibility Criteria

18 Years - 130 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses.
  • Participant must be ≥18 years (≥ 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted.
  • Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy.
  • Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M.
  • Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.
  • Mandatory provision of FFPE tumour tissue.
  • MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.
  • Measurable disease as defined by RECIST 1.1.
  • Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.
  • ECOG performance status of 0 or 1.

Exclusion Criteria:

  • Squamous NSCLC, and small cell lung cancer.
  • Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.
  • Prior or current treatment with savolitinib or another MET inhibitors.
  • Spinal cord compression or brain metastases, unless asymptomatic and are stable.
  • History or active leptomeningeal carcinomatosis.
  • Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 with the exception of alopecia, haemoglobin ≥ 9.0 g/dL, and Grade 2 prior platinum-therapy related neuropathy.
  • Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals.
  • History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement.
  • Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease.
  • Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention.
  • Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD.
  • Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2.

Sites / Locations

  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Chemotherapy

Savolitinib + Osimertinib

Arm Description

Pemetrexed (500 mg/m2) with either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles (Q3W) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) Q3W

300 mg savolitinib BID plus 80 mg osimertinib QD

Outcomes

Primary Outcome Measures

Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib.
Defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. PFS is assessed by Investigator.

Secondary Outcome Measures

Overall Survival (OS) /savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
Defined as time from randomisation until the date of death due to any cause.
Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed, locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
Defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. PFS is assessed by Investigator.
Overall Survival (OS) / savolitinib in combination with osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed by IHC, locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
Defined as time from randomisation until the date of death due to any cause.
Objective response rate (ORR) savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
ORR defined as the proportion of participants who have BOR of a CR or PR, as determined by BICR per RECIST 1.1.
Participant-reported pulmonary core symptoms / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib.
TTD in pulmonary core symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ. TTD is defined as the time from randomisation until the date of deterioration.
Pharmacokinetics (PK) of savolitinib.
Plasma concentrations of savolitinib and its metabolites.
Disease control rate (DCR) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
DCR defined as the proportion of participants who have BOR of a CR, PR, or stable disease, as determined by BICR per RECIST 1.1.
Time to discontinuation of treatment (TDT) or death / savolitinib + osimertinib vs platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on osimertinib
TDT or death is defined as the time from date of randomisation to the earlier of the date of study intervention discontinuation or death.
Tumor shrinkage / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
Tumour shrinkage defined as percentage change in tumour size in accordance with RECIST 1.1.
Duration of response (DoR) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
DoR defined as the time from the date of first documented response until date of documented progression per RECIST 1.1 as assessed by BICR, or death in the absence of disease progression.

Full Information

First Posted
February 15, 2022
Last Updated
October 16, 2023
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT05261399
Brief Title
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Acronym
SAFFRON
Official Title
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 3, 2022 (Actual)
Primary Completion Date
May 30, 2025 (Anticipated)
Study Completion Date
November 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Detailed Description
This is a multicentre, Phase III, randomised, open-label study to investigate the efficacy and safety of savolitinib administered orally in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on first- or second-line treatment with osimertinib as the most recent therapy. Approximately 324 participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC will be randomly assigned to study intervention with 1:1 ratio. Patients will be treated until either objective progression of disease (PD) by Response Evaluation Criteria in Solid Tumours 1.1 (RECIST 1.1) is assessed by the investigator, unacceptable toxicity occurs, consent is withdrawn, or another discontinuation criterion is met.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carcinoma, Non-Small-Cell Lung
Keywords
Savolitinib, Osimertinib, EGFR, Amplified, Metastatic, MET Driven, carcinoma, NSCLC, overexpressed

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Parallel Assignment
Masking
None (Open Label)
Masking Description
Open label
Allocation
Randomized
Enrollment
324 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Chemotherapy
Arm Type
Active Comparator
Arm Description
Pemetrexed (500 mg/m2) with either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles (Q3W) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) Q3W
Arm Title
Savolitinib + Osimertinib
Arm Type
Experimental
Arm Description
300 mg savolitinib BID plus 80 mg osimertinib QD
Intervention Type
Drug
Intervention Name(s)
Savolitinib
Other Intervention Name(s)
AZD6094, HMPL-504, volitinib
Intervention Description
300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
Intervention Type
Drug
Intervention Name(s)
Osimertinib
Other Intervention Name(s)
AZD9291, Tagrisso
Intervention Description
80 mg osimertinib (1 × 80 mg tablet once daily) Administrative route : oral
Intervention Type
Drug
Intervention Name(s)
Pemetrexed
Other Intervention Name(s)
NAP
Intervention Description
Pemetrexed (500 mg/m2) Administrative route : IV infusion
Intervention Type
Drug
Intervention Name(s)
Cisplatin
Other Intervention Name(s)
NAP
Intervention Description
Cisplatin (75 mg/m2) or Administrative route : IV infusion
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Other Intervention Name(s)
NAP
Intervention Description
Carboplatin (AUC5) Administrative route : IV infusion
Primary Outcome Measure Information:
Title
Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib.
Description
Defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. PFS is assessed by Investigator.
Time Frame
Approximately 55 months post first subject randomized
Secondary Outcome Measure Information:
Title
Overall Survival (OS) /savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
Description
Defined as time from randomisation until the date of death due to any cause.
Time Frame
Approximately 55 months post first subject randomized.
Title
Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed, locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
Description
Defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. PFS is assessed by Investigator.
Time Frame
Approximately 55 months post first subject randomized
Title
Overall Survival (OS) / savolitinib in combination with osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed by IHC, locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
Description
Defined as time from randomisation until the date of death due to any cause.
Time Frame
Approximately 55 months post first subject randomized
Title
Objective response rate (ORR) savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
Description
ORR defined as the proportion of participants who have BOR of a CR or PR, as determined by BICR per RECIST 1.1.
Time Frame
Approximately 55 months post first subject randomized
Title
Participant-reported pulmonary core symptoms / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib.
Description
TTD in pulmonary core symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ. TTD is defined as the time from randomisation until the date of deterioration.
Time Frame
Approximately 55 months post first subject randomized
Title
Pharmacokinetics (PK) of savolitinib.
Description
Plasma concentrations of savolitinib and its metabolites.
Time Frame
6 weeks after last patient dosed
Title
Disease control rate (DCR) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
Description
DCR defined as the proportion of participants who have BOR of a CR, PR, or stable disease, as determined by BICR per RECIST 1.1.
Time Frame
Approximately 55 months post first subject randomized
Title
Time to discontinuation of treatment (TDT) or death / savolitinib + osimertinib vs platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on osimertinib
Description
TDT or death is defined as the time from date of randomisation to the earlier of the date of study intervention discontinuation or death.
Time Frame
Approximately 55 months post first subject randomized
Title
Tumor shrinkage / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
Description
Tumour shrinkage defined as percentage change in tumour size in accordance with RECIST 1.1.
Time Frame
Approximately 55 months post first subject randomized
Title
Duration of response (DoR) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib.
Description
DoR defined as the time from the date of first documented response until date of documented progression per RECIST 1.1 as assessed by BICR, or death in the absence of disease progression.
Time Frame
Approximately 55 months post first subject randomized

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
130 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses. Participant must be ≥18 years (≥ 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted. Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy. Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M. Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy. Mandatory provision of FFPE tumour tissue. MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment. Measurable disease as defined by RECIST 1.1. Adequate haematological, liver, renal and cardiac functions, and coagulation parameters. ECOG performance status of 0 or 1. Exclusion Criteria: Predominant squamous NSCLC, and small cell lung cancer. Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib. Prior or current treatment with savolitinib or another MET inhibitors. Spinal cord compression or brain metastases, unless asymptomatic and are stable. History or active leptomeningeal carcinomatosis. Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 with the exception of alopecia, haemoglobin ≥ 9.0 g/dL, and Grade 2 prior platinum-therapy related neuropathy. Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals. History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement. Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease. Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention. Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD. Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
AstraZeneca Clinical Study Information Center
Phone
1-877-240-9479
Email
information.center@astrazeneca.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shun Lu, Prof,MD,PhD,
Organizational Affiliation
Shanghai Chest Hospital, Shanghai JiaoTong University, #241 Huai Hai Road (west), Shanghai, China.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Site
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Orange City
State/Province
Florida
ZIP/Postal Code
32763
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32804
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96819
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Evergreen Park
State/Province
Illinois
ZIP/Postal Code
60805
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Florham Park
State/Province
New Jersey
ZIP/Postal Code
07932
Country
United States
Individual Site Status
Withdrawn
Facility Name
Research Site
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08903
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Berazategui
ZIP/Postal Code
B1884BBF
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
Caba
ZIP/Postal Code
C1019ABS
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ciudad Autonoma De Buenos Aire
ZIP/Postal Code
C1125ABD
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
Cordoba
ZIP/Postal Code
X5004APD
Country
Argentina
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Florida
ZIP/Postal Code
B1602DQD
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
La Rioja
ZIP/Postal Code
F5300COE
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
Rosario
ZIP/Postal Code
2000
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
Rosario
ZIP/Postal Code
2123
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
San Miguel de Tucumán
ZIP/Postal Code
4000
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
Viedma
ZIP/Postal Code
R8500ACE
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Research Site
City
Fremantle
ZIP/Postal Code
6160
Country
Australia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Geelong
ZIP/Postal Code
3220
Country
Australia
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Liverpool
ZIP/Postal Code
2170
Country
Australia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Waratah NSW
ZIP/Postal Code
2298
Country
Australia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Graz
ZIP/Postal Code
8036
Country
Austria
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Individual Site Status
Recruiting
Facility Name
Research Site
City
Wien
ZIP/Postal Code
1140
Country
Austria
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Edegem
ZIP/Postal Code
B-2650
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Research Site
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hasselt
ZIP/Postal Code
3500
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Research Site
City
Mons
ZIP/Postal Code
7000
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Research Site
City
Roeselare
ZIP/Postal Code
8800
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sint-Niklaas
ZIP/Postal Code
9100
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Research Site
City
Belo Horizonte
ZIP/Postal Code
30110-022
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Brasilia
ZIP/Postal Code
70390-700
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Cachoeiro de Itapemirim
ZIP/Postal Code
29308-014
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Curitiba
ZIP/Postal Code
80810-050
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Ijuí
ZIP/Postal Code
98700-000
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ipatinga
ZIP/Postal Code
35162-189
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90035-903
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90050-170
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90540-140
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Rio De Janeiro
ZIP/Postal Code
20231-050
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Rio De Janeiro
ZIP/Postal Code
22793-080
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Salvador
ZIP/Postal Code
41253-190
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Salvador
ZIP/Postal Code
41950-610
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
São Paulo
ZIP/Postal Code
04014-002
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
São Paulo
ZIP/Postal Code
04538-132
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
São Paulo
ZIP/Postal Code
04556-100
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Vitória
ZIP/Postal Code
29043-260
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Haskovo
ZIP/Postal Code
6300
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Research Site
City
Pleven
ZIP/Postal Code
5804
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Research Site
City
Plovdiv
ZIP/Postal Code
4002
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sofia
ZIP/Postal Code
1407
Country
Bulgaria
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Varna
ZIP/Postal Code
9010
Country
Bulgaria
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Vratsa
ZIP/Postal Code
3000
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Research Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Name
Research Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Individual Site Status
Recruiting
Facility Name
Research Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1M5
Country
Canada
Individual Site Status
Recruiting
Facility Name
Research Site
City
Santiago
ZIP/Postal Code
7500713
Country
Chile
Individual Site Status
Recruiting
Facility Name
Research Site
City
Temuco
ZIP/Postal Code
4800827
Country
Chile
Individual Site Status
Recruiting
Facility Name
Research Site
City
Baoding
ZIP/Postal Code
71030
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Beijing
ZIP/Postal Code
100036
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Beijing
ZIP/Postal Code
101149
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Changchun
ZIP/Postal Code
130012
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Changsha
ZIP/Postal Code
410013
Country
China
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Changsha
ZIP/Postal Code
41003
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chengdu
ZIP/Postal Code
610041
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chongqing
ZIP/Postal Code
400016
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Fuzhou
ZIP/Postal Code
350001
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Fuzhou
ZIP/Postal Code
350011
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hangzhou
ZIP/Postal Code
310022
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hankou,Wuhan
ZIP/Postal Code
430022
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Harbin
ZIP/Postal Code
150040
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hefei
ZIP/Postal Code
230031
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Jinan
ZIP/Postal Code
250022
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Linyi
ZIP/Postal Code
276000
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Nanchang
ZIP/Postal Code
330006
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Qingdao
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shanghai
ZIP/Postal Code
200030
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shenyang
ZIP/Postal Code
110001
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Wuhan
ZIP/Postal Code
430079
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Xiangfan
ZIP/Postal Code
441021
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Xian
ZIP/Postal Code
710100
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Zhengzhou
ZIP/Postal Code
450008
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Angers
ZIP/Postal Code
49933
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Bobigny
ZIP/Postal Code
93000
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Bordeaux Cedex
ZIP/Postal Code
33076
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Brest
ZIP/Postal Code
29200
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Creteil
ZIP/Postal Code
94010
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Dijon
ZIP/Postal Code
21079
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Marseille
ZIP/Postal Code
13915
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Montpellier
ZIP/Postal Code
34298
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Paris
ZIP/Postal Code
75005
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Paris
ZIP/Postal Code
75018
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Poitiers
ZIP/Postal Code
86021
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Rennes Cedex 9
ZIP/Postal Code
35033
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Rouen
ZIP/Postal Code
76000
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Saint-Herblain
ZIP/Postal Code
44800
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Saint-Quentin cedex
ZIP/Postal Code
02321
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Strasbourg Cedex
ZIP/Postal Code
67091
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Suresnes
ZIP/Postal Code
92150
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
14165
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chemnitz
ZIP/Postal Code
09113
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Frankfurt A. Main
ZIP/Postal Code
60590
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Gauting
ZIP/Postal Code
82131
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Homburg
ZIP/Postal Code
66424
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Immenhausen
ZIP/Postal Code
34376
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Löwenstein
ZIP/Postal Code
74245
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Muenster
ZIP/Postal Code
48149
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
München
ZIP/Postal Code
81925
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Stuttgart
ZIP/Postal Code
70376
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Wangen
ZIP/Postal Code
88239
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Athens
ZIP/Postal Code
115 27
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Athens
ZIP/Postal Code
11527
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chaidari
ZIP/Postal Code
124 62
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Heraklion
ZIP/Postal Code
71110
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Larissa
ZIP/Postal Code
41110
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Rio
ZIP/Postal Code
265 04
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Thessaloniki
ZIP/Postal Code
546 39
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Thessaloniki
ZIP/Postal Code
54622
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Afula
ZIP/Postal Code
18341
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ashdod
ZIP/Postal Code
7747629
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Be'er Ya'akov
ZIP/Postal Code
70300
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hadera
ZIP/Postal Code
38100
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Jerusalem
ZIP/Postal Code
91031
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Tel Aviv
ZIP/Postal Code
6423906
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Avellino
ZIP/Postal Code
83100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Aviano
ZIP/Postal Code
33081
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Catania
ZIP/Postal Code
95123
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Meldola
ZIP/Postal Code
47014
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Milano
ZIP/Postal Code
20133
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Milan
ZIP/Postal Code
20141
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Modena
ZIP/Postal Code
41124
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Monserrato
ZIP/Postal Code
09042
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Napoli
ZIP/Postal Code
80138
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Orbassano
ZIP/Postal Code
10043
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Padova
ZIP/Postal Code
35128
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Parma
ZIP/Postal Code
43126
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Peschiera Del Garda
ZIP/Postal Code
37019
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Roma
ZIP/Postal Code
00144
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Roma
ZIP/Postal Code
00152
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Treviso
ZIP/Postal Code
31100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Bunkyo-ku
ZIP/Postal Code
113-8603
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chuo-ku
ZIP/Postal Code
104-0045
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hirosaki-shi
ZIP/Postal Code
036-8563
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hiroshima-shi
ZIP/Postal Code
730-8518
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Iwakuni-shi
ZIP/Postal Code
740-8510
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kanazawa-shi
ZIP/Postal Code
920-8641
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kobe-shi
ZIP/Postal Code
650-0017
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kobe
ZIP/Postal Code
650-0046
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kumamoto-shi
ZIP/Postal Code
860-8556
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kurume-shi
ZIP/Postal Code
830-0011
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Matsuyama
ZIP/Postal Code
791-0288
Country
Japan
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Nagasaki-shi
ZIP/Postal Code
852-8501
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Okayama-shi
ZIP/Postal Code
700-8558
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Osaka-shi
ZIP/Postal Code
534-0021
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Osakasayama-shi
ZIP/Postal Code
589-8511
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sakai-shi
ZIP/Postal Code
591-8555
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sapporo-shi
ZIP/Postal Code
003-0804
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sapporo-shi
ZIP/Postal Code
060-8638
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sendai-shi
ZIP/Postal Code
980-0873
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sunto-gun
ZIP/Postal Code
411-8777
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Utsunomiya-shi
ZIP/Postal Code
320-0834
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Wakayama-shi
ZIP/Postal Code
641-8510
Country
Japan
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Yokohama-shi
ZIP/Postal Code
241-8515
Country
Japan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Goyang-si
ZIP/Postal Code
10408
Country
Korea, Republic of
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Gyeonggi-do
ZIP/Postal Code
13620
Country
Korea, Republic of
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Jinju-si
ZIP/Postal Code
660-702
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Research Site
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Seoul
ZIP/Postal Code
138-736
Country
Korea, Republic of
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Suwon
ZIP/Postal Code
16247
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ulsan
ZIP/Postal Code
44033
Country
Korea, Republic of
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Kota Bahru
ZIP/Postal Code
15586
Country
Malaysia
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Sabah
ZIP/Postal Code
88996
Country
Malaysia
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Amsterdam
ZIP/Postal Code
1066CX
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Bialystok
ZIP/Postal Code
15-003
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Krakow
ZIP/Postal Code
30-727
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Olsztyn
ZIP/Postal Code
10-357
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Łódź
ZIP/Postal Code
93-338
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chelyabinsk
ZIP/Postal Code
454087
Country
Russian Federation
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Moscow
ZIP/Postal Code
119881
Country
Russian Federation
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Saint Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Tomsk
ZIP/Postal Code
634050
Country
Russian Federation
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Badajoz
ZIP/Postal Code
6006
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Badalona
ZIP/Postal Code
8916
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Cordoba
ZIP/Postal Code
14004
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Girona
ZIP/Postal Code
17007
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
La Coruña
ZIP/Postal Code
15006
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Majadahonda
ZIP/Postal Code
28222
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Málaga
ZIP/Postal Code
29010
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Pontevedra
ZIP/Postal Code
36312
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sabadell
ZIP/Postal Code
08208
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
Individual Site Status
Recruiting
Facility Name
Research Site
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Winterthur
ZIP/Postal Code
8401
Country
Switzerland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Zürich
ZIP/Postal Code
8063
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Chiayi
ZIP/Postal Code
62247
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hsinchu
ZIP/Postal Code
300
Country
Taiwan
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Liuying
ZIP/Postal Code
736
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Taichung
ZIP/Postal Code
404
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Taichung
ZIP/Postal Code
40705
Country
Taiwan
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Taipei 112
Country
Taiwan
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Taipei City
ZIP/Postal Code
11259
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Taipei
ZIP/Postal Code
100
Country
Taiwan
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Bangkok
ZIP/Postal Code
10210
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chiang Mai
ZIP/Postal Code
50200
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Dusit
ZIP/Postal Code
10300
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hat Yai
ZIP/Postal Code
90110
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Muang
ZIP/Postal Code
40002
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Mueang Chanthaburi
ZIP/Postal Code
22000
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Adana
ZIP/Postal Code
1370
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ankara
ZIP/Postal Code
6800
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Edirne
ZIP/Postal Code
22030
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Istanbul
ZIP/Postal Code
34214
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Istanbul
ZIP/Postal Code
34722
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Izmir
ZIP/Postal Code
35100
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Research Site
City
Leicester
ZIP/Postal Code
LE1 5WW
Country
United Kingdom
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Liverpool
ZIP/Postal Code
L7 3EW
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Newport
ZIP/Postal Code
NP10 8FZ
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Reading
ZIP/Postal Code
RG2 9LH
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Hanoi City
ZIP/Postal Code
100000
Country
Vietnam
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hanoi
ZIP/Postal Code
100000
Country
Vietnam
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Hanoi
ZIP/Postal Code
10000
Country
Vietnam
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Ho Chi Minh city
ZIP/Postal Code
700000
Country
Vietnam
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Ho Chi Minh
ZIP/Postal Code
70000
Country
Vietnam
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing URL
https://astrazenecagroup-dt.pharmacm.com/DT/Home

Learn more about this trial

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

We'll reach out to this number within 24 hrs